LP
NAVB

LMR Partners’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

LMR Partners’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,179
Closed -$151K – 549
2016
Q2 		$151K Buy
+14,179
New +$279K 0.02% 374

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

LMR Partners's NAVB Position: Q3 2016 in Review

LMR Partners sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 14,179 shares — an estimated $151K sold.

LMR Partners first reported a position in NAVB in Q2 2016 and held it in 1 quarter. The position peaked at $151K in Q2 2016. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

  • LMR Partners reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • LMR Partners sold 14,179 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $151K.
  • LMR Partners first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 1 quarter.
  • LMR Partners's Navidea Biopharmaceuticals Inc. position peaked at $151K in Q2 2016.
  • 55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on LMR Partners's 13F filing for Q3 2016, filed 1 Nov 2016.